| Metastatic Colorectal Cancer |
1 |
1 |
| Antineoplastic Drug |
0 |
0.99 |
| Biologic Therapy |
0 |
0.95 |
| Colorectal Cancer |
0 |
0.9 |
| Breast Cancer |
0 |
0.86 |
| Cancer |
0 |
0.73 |
| Humanized Monoclonal Antibody |
0 |
0.59 |
| Noncolorectal Gastrointestinal Cancer |
0 |
0.59 |
| Targeted Cancer Therapy |
0 |
0.59 |
| Head and Neck Cancer |
0 |
0.55 |
| Metastasis |
0 |
0.55 |
| Colon Cancer |
0 |
0.54 |
| Gastric Cancer |
0 |
0.54 |
| Gastrointestinal Cancer |
0 |
0.54 |
| HER2-Positive Breast Cancer |
0 |
0.52 |
| Genomic Medicine |
0 |
0.44 |
| Breast |
0 |
0.14 |
| Clinical Research |
0 |
0.1 |
| Epidermal Growth Factor Receptor |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| Tyrosine Kinase Inhibitor |
0 |
0.1 |
| Brain Metastasis |
0 |
0.08 |
| Adverse Effects |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |
| Revenue and Practice Management |
0 |
0.07 |
| Tyrosine Kinase |
0 |
0.07 |
| Abdominal Pain |
0 |
0.06 |
| Pain Management |
0 |
0.06 |